Louisiana 2026 Regular Session

Louisiana Senate Bill SB26

Introduced
2/3/26  
Refer
2/3/26  
Refer
3/9/26  
Report Pass
3/11/26  
Engrossed
3/18/26  
Refer
3/23/26  
Report Pass
4/29/26  
Enrolled
5/12/26  
Chaptered
5/15/26  

Caption

Provides relative to opioid treatment programs. (gov sig)

Impact

The repeal of these requirements may have significant implications for state healthcare regulations. By removing the facility need review process, the bill could facilitate the establishment of more treatment programs, which advocates argue is essential in addressing the opioid crisis. However, this change also raises concerns about regulatory oversight and the quality of care provided at newly established facilities. The removal of such requirements could result in a quicker proliferation of treatment centers, but critics fear that it may lead to inadequately managed programs lacking necessary standards.

Summary

Senate Bill No. 26 (SB26), introduced by Senator McMath, aims to repeal certain regulations associated with opioid treatment programs in Louisiana. Specifically, it seeks to eliminate the facility need review requirements, which are intended to assess the necessity for new opioid treatment facilities before their establishment. The intent of this legislation is to streamline the process for creating and operating such facilities, thereby potentially increasing access to treatment for individuals struggling with opioid addiction.

Sentiment

General sentiment surrounding SB26 appears to be supportive among stakeholders focused on improving access to opioid treatment options. Proponents argue that easing restrictions on facility establishment is crucial for responding to the ongoing opioid epidemic, signaling a need for action to provide adequate resources for rehabilitation. However, there exists apprehension regarding the quality of care that may arise from this lack of oversight, leading to a polarized view among healthcare providers and regulatory bodies concerning the bill's potential outcomes.

Contention

Arguments against SB26 center on the potential for compromising standards within opioid treatment facilities. Opponents highlight the risks of unchecked expansion and the need for oversight to ensure facilities provide safe and effective treatment. There is a fear that without the facility need review requirements, the system may be exploited, resulting in subpar care that does not meet the necessary standards for patient recovery. The debate emphasizes the balance between expanding access to care and maintaining regulatory safeguards to protect patients.

Companion Bills

No companion bills found.

Previously Filed As

LA HB400

Provides relative to a minor's consent for medical procedures and treatments

LA SB65

Provides for the treatment of certain pass through entities under the inventory tax credit. (gov sig) (EN INCREASE SD RV See Note)

LA SB153

Provides relative to behavioral health rehabilitation services in the Louisiana medical assistance program. (gov sig)

LA SB78

Provides relative to drug paraphernalia. (gov sig)

LA SB94

Provides for waters of the state. (gov sig)

LA SB174

Provides relative to certain pregnancy screenings. (gov sig) (EN INCREASE GF EX See Note)

LA SB194

Provides relative to pharmacy benefit managers. (gov sig)

LA SB102

Provides relative to obstetric care. (gov sig) (OR INCREASE GF EX See Note)

LA SB104

Provides relative to the Empowering Families to Live Well Louisiana Council. (gov sig)

LA SB19

Provides relative to the dispensing of ivermectin. (gov sig)

Similar Bills

No similar bills found.